January 24, 2018 — In a perspective piece in the New England Journal of Medicine, CP3 Director Walid Gellad and HPI Director Everette James describe the controversy surrounding the 340B Drug Pricing Program. A recent CMS rule will reduce Medicare Part B payments to hospital outpatient departments for Read More »